Cell line for culturing african swine fever virus and vaccine using same

The CA-CAS-01-A cell line addresses the challenge of ASFV cultivation and vaccine production by enabling efficient ASFV propagation and producing a naturally attenuated vaccine, offering enhanced protection against African swine fever.

WO2024248170A1PCT designated stage expired Publication Date: 2024-12-05CHOONGANG VACCINE LABORATORY CO LTD
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
PCT/KR2023/007253
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Filing Date
2023-05-26
Publication Date
2024-12-05

AI Technical Summary

Technical Problem

Developing an effective cell line for cultivating African swine fever virus (ASFV) is challenging due to its diverse genotypes and complex structure, making it difficult to culture and produce vaccines, with existing cell lines like Vero showing low viral proliferation and inadequate protective efficacy.

Method used

Establishment of the CA-CAS-01-A cell line, derived from the MA104 cell line, which is capable of continuous ASFV propagation and produces naturally attenuated virus, allowing for mass production of ASFV and the development of a vaccine.

Benefits of technology

The CA-CAS-01-A cell line enables efficient ASFV propagation and production of a naturally attenuated vaccine, providing effective protection against African swine fever with improved viral proliferation and stability, as demonstrated by successful virus titers and immune response in pigs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure KR2023007253_05122024_PF_FP_ABST
    Figure KR2023007253_05122024_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to a CA-CAS-01-A cell line deposited with an accession number of 14568 BP capable of mass-proliferating African swine fever virus (ASFV), and a use thereof. The cell line of the present invention and ASFV produced therefrom can be usefully used for preventing and alleviating damage from African swine fever.
Need to check novelty before this filing date? Find Prior Art

Description

Cell lines for culturing African swine fever virus and vaccines using the same

[0001] The present invention relates to a cell line for culturing African swine fever virus and a vaccine using the same.

[0002]

[0003] This research was supported by the Ministry of Agriculture, Food and Rural Affairs' Livestock Disease Response Technology Development Project (Project Number: 119081053SB010).

[0004] African swine fever (ASF) is a viral hemorrhagic disease of pigs that infects only animals belonging to the pig family (Suidae) and is primarily transmitted directly through secretions from infected pigs. African swine fever virus (ASFV) is the causative agent of African swine fever, and is generally classified as highly pathogenic, moderately pathogenic, or low pathogenic based on pathogenicity. Highly pathogenic strains usually cause severe acute (pigs die 1-4 days after infection) and acute (pigs die 3-8 days after infection) disease, while moderately pathogenic strains cause acute (pigs die 11-15 days after infection) and subacute (pigs die 20 days after infection) disease. Low pathogenic strains have only been reported in endemic areas and cause subclinical or chronic disease. Mortality rates are known to be nearly 100% in highly pathogenic strains and less than 20% in chronic strains. ASFV is a species of the Asfarviridae family, a virus with a double-stranded DNA genome. It is a relatively large virus with over 189 genes within 189,000 base pairs and an icosahedral structure, and is known to have 23 genotypes.

[0005] To develop a vaccine to prevent or treat African swine fever, various research groups have conducted various studies, including vaccine development using blood leukocytes, purified and inactivated virions, infected glutaraldehyde-fixed macrophages, culture supernatants of detergent-treated infected alveolar macrophages, DNA vaccines, attenuated live virus vaccines, inactivated vaccines, or viral vectors. However, ASFV has a diverse genotype and complex structure, and has difficulty infecting general cells. Therefore, culturing or isolating the virus for vaccine production using PAM primary cells, which are known to be susceptible to the virus, is extremely difficult. While ASFV Georgia strains have been known to adapt and proliferate in Vero cells, their protective efficacy as a vaccine is known to be significantly reduced. ASFV Spanish strains have also been found to be unsuitable for vaccine production. In general, it is difficult to increase the viral proliferation rate of ASFV through additional subculture, and ASFV adapted for more than 100 passages in Vero cell lines is known to have good stability and proliferation in cells, but does not show substantial protective effects when vaccinated.

[0006] Meanwhile, Korean Patent Publication No. 2011-0123918 discloses 'PAM-pCD163 cell line for isolating porcine reproductive and respiratory syndrome virus and vaccine using the same', and Korean Patent Publication No. 2015-0019910 discloses 'Immortalized pig kidney-derived cell line and method for propagating porcine circovirus type 2 using the same', but 'cell line for culturing African swine fever virus and vaccine using the same' of the present invention is not described.

[0007] The present invention was derived from the above-mentioned needs, and in order to establish a cell line capable of proliferating African swine fever virus (ASFV), the inventors infected various kidney cell lines derived from animals with ASFV and continued to subculture to confirm the isolation and proliferation of ASFV. As a result, they confirmed that the MA104 cell line (Africa green monkey kidney cell) could continuously proliferate ASFV for more than 10 passages compared to other kidney cell lines. In addition, among single cell clones derived from the MA104 cell line, a single cell clone having a superior ASFV proliferative ability compared to other clones and having the characteristic of producing naturally attenuated ASFV was confirmed, and this single cell clone was named CA-CAS-01-A cell line, thereby completing the present invention.

[0008] To solve the above problem, the present invention provides a CA-CAS-01-A cell line deposited under the accession number KCTC14568BP, which is capable of mass-producing African swine fever virus.

[0009] In addition, the present invention provides a method for mass production of African swine fever virus, which comprises a step of infecting the cell line with African swine fever virus and then culturing the cell line.

[0010] In addition, the present invention provides a vaccine composition comprising African swine fever virus produced by the above method.

[0011] The CA-CAS-01-A cell line of the present invention is a new cell line for propagating African swine fever virus (ASFV) capable of isolating and culturing ASFV. The ASFV produced (incubated) from the cell line of the present invention is a naturally attenuated form without pathogenicity, and can be usefully used for preventing and reducing damage from African swine fever.

[0012] Figure 1 shows the results of susceptibility to African swine fever virus (ASFV) of various cell lines. A shows the results of confirming the ASFV gene expression level for each cell line according to passage, and B is a photograph of each cell line at passage 1. The number in the upper right of the B image indicates the susceptibility of each cell expressed as a Ct value by measuring the ASF virus P72 gene in real time, and the part confirmed as the ASF virus P30 gene in the cytoplasm after ASF virus infection is indicated by an arrow.

[0013] Figure 2A shows the susceptibility of MA104 parental cells and MA104-derived single cell clones to ASFV as measured by Ct values ​​and TCID 50 This is the result of analysis at 7 passages, and Figure 2B shows the results of susceptibility analysis of Marc145, Vero, and COS cells and their single cell clones to ASFV. CAS-01 (=CA-CAS-01-A) and C1~C12: MA104 single cell clone, M1~3: Marc145 single cell clone, V1 and V2: Vero single cell clone, S1 and S2: COS single cell clone.

[0014] Figure 3 shows the TCID analysis of virus titer according to passage in CA-CAS-01-A cell line infected with ASFV isolate. 50 This is the result.

[0015] Figure 4 shows cell photographs showing the cell adaptation process according to passages 1, 2, 4, 6, and 10 of two domestic isolates (Korea.Pig.Yeoncheon1-FC.2019 and Korea.Pig.Paju1-FC.2019) and one Vietnamese isolate (Vietam.Pig.Hochiminh-KVL.2019) in CA-CAS-01-A cell line using the ASF virus P30 gene.

[0016] Figure 5 is a schematic diagram showing the genomic deletion region of ASFV produced in CA-CAS-01-A cell line infected with ASFV isolate (Korea.Pig.Yeoncheon1-FC.2019). ASFV.Yc1_FC p1: ASFV recovered after 1 passage, ASFV-CAP-YC p9: ASFV recovered after 9 passages, ASFV-CAP-YC p13: ASFV recovered after 13 passages.

[0017] Figure 6 shows the results of analyzing the body temperature (A) and survival rate (B) of pigs inoculated with ASFV produced from the CA-CAS-01-A cell line.

[0018] Figure 7 shows the results of confirming the virus titer in oral swab (A), rectal swab (B), nasal swab (C), serum (D), and whole blood (E) of pigs inoculated with ASFV produced in the CA-CAS-01-A cell line.

[0019] In order to achieve the purpose of the present invention, the present invention provides a CA-CAS-01-A cell line deposited under the accession number KCTC14568BP, which is capable of mass-producing African swine fever virus (ASFV).

[0020] The CA-CAS-01-A cell line according to the present invention is derived from the MA104 cell line (African green monkey kidney cell line), and was established from a cell clone capable of ASFV proliferation even after continuous subculture (up to passage 16) by infecting MA104 cells with an ASFV isolate (field strain) and observing virus proliferation while subculturing. In addition, the CA-CAS-01-A cell line was infected with the ASFV field strain (Korea.Pig.Yeoncheon1-FC.2019), but the produced virus, ASFV-CAP-YC, is characterized by being naturally attenuated. Accordingly, the present inventors deposited the CA-CAS-01-A cell line with the Biological Resource Center of the Korea Research Institute of Bioscience and Biotechnology on May 12, 2021 (Accession No. KCTC14568BP).

[0021] The term "attenuation" refers to mutations in genes involved in essential metabolic processes of a pathogen, rendering it incapable of causing disease in the body and instead stimulating the immune system to induce immunity. Viral attenuation can be achieved through methods such as ultraviolet (UV) irradiation, chemical treatment, or high-throughput serial passage in vitro. Attenuation can also be achieved by making specific genetic changes, such as the deletion of specific viral sequences known to confer virulence or the insertion of sequences into the viral genome.

[0022] The present invention also comprises: (a) a step of infecting the CA-CAS-01-A cell line with an African swine fever virus (ASFV) isolate and then culturing it; and

[0023] (b) a step of purifying African swine fever virus from the culture solution of step (a); a method for mass production of African swine fever virus is provided.

[0024] In a method according to one embodiment of the present invention, the ASFV isolate of step (a) may preferably be, but is not limited to, the Korea.Pig.Yeoncheon1-FC.2019, Korea.Pig.Paju1-FC.2019 or Vietnam.Pig.Hochiminh.KVL.2019 isolate.

[0025] In addition, the above infection may be performed by treating the CA-CAS-01-A cell line with a culture medium of ASFV or a homogenate of animal tissue infected with ASFV, but is not limited thereto. The time required for infection and the period of virus replication may vary depending on the type of virus, and the time required for infection is generally about 3 to 12 hours, and the period of replication is 3 to 7 days.

[0026] Additionally, in the method according to the present invention, the ASFV in step (b) may be naturally attenuated, but is not limited thereto.

[0027] In addition, the culture of the CA-CAS-01-A cell line can be performed using a conventional method and known medium known in the art.

[0028] In the method according to the present invention, when infection and proliferation by the ASFV are completed, CA-CAS-01-A cells and culture supernatant are collected and purified using a conventional method to recover ASFV.

[0029] The present invention also provides a vaccine composition comprising African swine fever virus produced by the above method.

[0030] The vaccine composition according to the present invention can be manufactured using a proliferated virus culture obtained from the culture stage of the CA-CAS-01-A cell line infected with ASFV, and can be manufactured in the form of a live vaccine or an inactivated vaccine. In the case of an inactivated vaccine, the virus is inactivated by a specific method such as treatment with formalin or binary ethyleneimine (BEI), the inactivated virus is purified by a conventional method, and a sterility test and a virus content test are performed on the virus stock solution, and a preservative and a buffered saline solution are added to dilute and mix, or a stabilizer is added to manufacture the vaccine.

[0031] Since the ASFV produced using the CA-CAS-01-A cell line according to the present invention is a naturally attenuated virus, the vaccine composition may preferably be in the form of an attenuated live vaccine, but is not limited thereto.

[0032] Attenuated vaccines are vaccines in which the pathogen's virulence is reduced but still remains live. Live attenuated vaccines have the advantage of being able to induce both antibody and cellular immune responses, and their sustained immunogenicity reduces the need for adjuvant injections to boost efficacy.

[0033] In a vaccine composition according to one embodiment of the present invention, the naturally attenuated ASFV produced using the CA-CAS-01-A cell line is MGF110-3L partial, MGF 110-4L, MGF 1105L6L, MGF 110-7L, 285L, ASFV G ACD 00160, MGF 100-1R, ASFV G ACD 00190, MGF 110-9L, MGF 110-11L_14L, ASFV G ACD 00240 MGF 110-12L, MGF 110-13La_b, ASFV G ACD 00270, MGF 360-4L, MGF 360-6L, MGF 300-1L, MGF 300-2R, MGF One or more genes selected from the group consisting of 300-4L, MGF 360-8L, MGF 360-9L, MGF 360-10L, MGF 360-11L, MGF 505-1R, L7L, L8L, L9R, L10L and L11 may be defective, and more preferably MGF110-3L partial, MGF 110-4L, MGF 1105L6L, MGF 110-7L, 285L, ASFV G ACD 00160, MGF 100-1R, ASFV G ACD 00190, MGF 110-9L, MGF 110-11L_14L, ASFV G ACD 00240 MGF 110-12L, MGF 110-13La_b, ASFV G ACD 00270, MGF 360-4L, MGF 360-6L, MGF 300-1L, MGF 300-2R, MGF 300-4L, MGF 360-8L, MGF 360-9L, MGF 360-10L, MGF 360-11L, MGF 505-1R, L7L, L8L, L9R, L10L and L11 genes may all be deleted and thus attenuated, but are not limited thereto.

[0034] The naturally attenuated ASFV of the present invention may have deletions of bases 8,460 to 29,258 (deletion 1) and bases 181,463 to 184,693 (deletion 2) based on the sequence of African swine fever virus isolate ASFV Georgia 2007 / 1 genome assembly, complete genome (NCBI Reference Sequence: NC_044959.2), and a number of genes related to the above-described attenuation are contained within the deletions 1 and 2.

[0035] Additionally, the vaccine composition of the present invention may further comprise a pharmaceutically acceptable carrier and / or adjuvant. Furthermore, in addition to the carrier, the vaccine composition of the present invention may further comprise an excipient and / or diluent.

[0036] The term "pharmaceutically acceptable" as used herein refers to a substance that is physiologically tolerable and does not typically cause allergic reactions such as gastrointestinal upset or dizziness or similar reactions when administered to humans. Examples of such carriers, excipients, and diluents include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, polyvinylpyrrolidone, water, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate, and mineral oil. In addition, fillers, anticoagulants, lubricants, wetting agents, flavoring agents, emulsifiers, and preservatives may be additionally included.

[0037] The above "adjuvant" refers to a pharmaceutical or immunological preparation administered for the purpose of enhancing the immune response of a vaccine. The adjuvant may include aluminum hydroxide, aluminum phosphate, alum (potassium aluminum sulfate), MF59, virosome, AS04 [a mixture of aluminum hydroxide and monophosphoryl lipid A (MPL)], AS03 (a mixture of DL-α-tocopherol, squalene, and polysorbate 80, an emulsifier), CpG, Flagellin, Poly I:C, AS01, AS02, ISCOMs, or ISCOMMATRIX.

[0038] The vaccine composition of the present invention can be formulated using methods known in the art to enable rapid, sustained, or delayed release of the active ingredient when administered to a mammal. Formulations include powders, granules, tablets, emulsions, syrups, aerosols, soft or hard gelatin capsules, sterile injectable solutions, and sterile powder forms.

[0039] The vaccine composition according to the present invention may be administered via various routes, including oral, parenteral, e.g., suppository, transdermal, intravenous, intraperitoneal, intramuscular, intralesional, nasal, and intrathecal administration. It may also be administered using an implantable device for sustained release, continuous, or repeated release. The frequency of administration may be once a day or divided into several doses within a desired range, and the administration period is not particularly limited.

[0040]

[0041] Hereinafter, the present invention will be described in detail by way of examples. However, the following examples are merely illustrative of the present invention, and the content of the present invention is not limited to the following examples.

[0042]

[0043] Example 1. Screening of susceptible cell lines according to infection with ASFV isolates.

[0044] The present inventors screened ASFV-susceptible cell lines for ASFV culture. The cell lines used were MA104, PAM, PK15, Marc145, Vero, and BHK CD163, all available from the Central Vaccine Research Institute. All cell lines were maintained in α-MEM (5% FBS, 1% antibiotics) at 37°C and 5% CO2, with subcultures performed every 2-3 days.

[0045] Cell line used in the present invention Cell line name Origin MA104 African green monkey kidney PAMPorcine macrophages PK15 Porcine kidney Marc145 A clone of the African green monkey kidney cell line MA-104 Vero African green monkey kidney epitherial BHK CD163 Baby Hamster kidney COSA African green monkey kidney fibroblast-like cell line

[0046] To determine the ASFV susceptibility of each cell line, 75 cm 2 1 x 10 cells per flask 6After preparing cells / well, ASFV culture (Animal and Plant Quarantine Agency: approximately 18 Ct value, Vietnam Raho-6: approximately 18 Ct value) was treated for infection. Subculture was performed at 37℃, 5% CO2 conditions at 7-day intervals, and cultures of passages 1, 3, 5, and 10 were collected, and the supernatants and cells were frozen at -80℃. After thawing once in a 37℃ water heater, qPCR (quantitative PCR) was performed using the cultures. During subculture, cells were infected using the cultures of the previous passage. qRCR was performed under the following conditions using a primer set specific for P72 of ASFV. Korea.Pig.Paju1-FC.2019, a domestic isolate, was used as a positive control.

[0047] Primer information used in qPCR Primer name Base sequence (5'→3') Sequence number P72_Forward CTG CTC ATG GTA TCA ATC TTA TCG A1 P72_Reverse GAT ACC ACA AGA TC(AG) GCC GT2

[0048] qPCR conditions Step Reaction Conditions Number of cycles Uracil-DNA Glycosylase (UNG) treatment 50℃, 2 min 1 cycle Denaturation 95℃, 10 min 1 cycle Denaturation 95℃, 15 sec 40 cycles Binding 58℃, 1 min

[0049] As a result, it was confirmed that only the MA104 cell line continuously propagated the ASFV virus even after the 10th passage (Fig. 1). Therefore, the MA104 cell line was used to establish a cell line for ASFV culture.

[0050]

[0051] Example 2. Comparison of ASFV-specific susceptibility between single-cell clones derived from the MA104 cell line.

[0052] The inventors of the present invention prepared a single cell clone by serially diluting the MA104 cell line, infected it with ASFV under the same conditions as Example 1, and performed a total of 7 subcultures. Then, qPCR was performed using a primer set specific to P72 of ASFV, and TCID 50 (tissue culture infective dose 50) The virus was quantified by experiment. In addition, Marc145 and Vero cell lines, which have the same parental cell line (MA104) as CAS-01, and their single-cell clones, and COS cell line derived from African green monkey kidney and its single-cell clone were infected and compared under the same conditions.

[0053] As a result, MA104 cells showed 6.9 log 10 TCID 50 / ㎖ concentration of virus was confirmed, and the cells named CAS-01 had a 7.5 log 10 TCID 50 / ml concentration of virus was confirmed. Also, the single cell clone derived from the same MA104, but named C10, had a 3.6 log 10 TCID 50 / mL concentration of virus was confirmed, confirming that there was a significant difference in virus proliferation by single cell clone (Fig. 2A). Marc145 and Vero cell lines were 6.5 log 10 TCID 50 / ㎖ and 4.5 log 10 TCID 50 / ㎖ concentration of virus was confirmed, and the COS cell line was 6.5 log 10 TCID 50 / ㎖ concentration of virus was confirmed (Fig. 2B). Through the above results, it was found that there are differences in virus susceptibility by single cell clone even in cell lines derived from the same source. For the propagation and culture of ASFV, CAS-01 cell line was selected for subsequent experiments. The cell line was named 'CA-CAS-01-A' and deposited with the Korea Center for Bioscience and Biotechnology (KCTC) on May 12, 2021 (Accession Number: KCTC 14568BP).

[0054]

[0055] Example 3. Virus proliferation in CA-CAS-01-A cell line according to passage after ASFV infection

[0056] The present inventors infected CA-CAS-01-A cell line with Korea.Pig.Yeoncheon1-FC.2019, Korea.Pig.Paju1-FC.2019, or Vietnam.Pig.Hochiminh.KVL.2019 isolates and analyzed the viral proliferation according to subculture. Each virus was provided by Dr. Yong-Joo Kim of the Animal and Plant Quarantine Agency. The virus infection concentration was the same as in Example 1.

[0057] As a result, the CA-CAS-01-A cell line infected with each initial ASFV isolate (passage 1) showed a virus titer of 5.2 log in the cultured Korea.Pig.Yeoncheon1-FC.2019 isolate. 10 TCID 50 / ㎖, Korea.Pig.Paju1-FC.2019 isolate and Vietnam.Pig.Hochiminh.KVL.2019 isolate were 4.5 log 10 TCID 50 / ㎖ concentration of virus was confirmed, and each ASFV isolate that was passaged 9 times in total was infected and the virus proliferation according to the day after infection was confirmed. As a result, on the 6th day after infection, 8.2 log for the Korea.Pig.Yeoncheon1-FC.2019 isolate 10 TCID 50 / ㎖, Korea.Pig.Paju1-FC.2019 isolate was 8.0 log 10 TCID 50 / ㎖ and 7.2 log for Vietnam.Pig.Hochiminh.KVL.2019 isolate 10 TCID 50 / ㎖ concentration of viruses was confirmed, and it was confirmed that all three viruses had significantly increased proliferation after adaptive passage in the CA-CAS-01-A cell line (Fig. 3 and Fig. 4).

[0058]

[0059] Example 4. Characteristics of ASFV propagated from CA-CAS-01-A cell line

[0060] In order to confirm the characteristics of ASFV propagated from CA-CAS-01-A cell line, the present inventors recovered viruses from cultures cultured 1, 9, and 13 times and analyzed their genome sequences using MiSeq System equipment (Illumina, USA) and CLC Genomics Workbench program. As a result, as shown in Fig. 5, it was confirmed that ASFV recovered after 9 and 13 times of passage (ASFV-CAP-YC p9 and ASFV-CAP-YC p13, respectively) had large gene deletions in the 5' and 3' regions, unlike the genome of the initially infecting virus. The genes located in each deletion region are shown in Table 4 below. In particular, many of the deleted genes were confirmed to be associated with attenuation.

[0061] ASFV (ASFV-CAP-YC) produced from CA-CAS-01-A cell line Gene deleted Deletion site 1MGF 110-3L partial, MGF 110-4L, MGF 1105L6L, MGF 110-7L, 285L, ASFV G ACD 00160, MGF 100-1R, ASFV G ACD 00190, MGF 110-9L, MGF 110-11L_14L, ASFV G ACD 00240 MGF 110-12L, MGF 110-13La_b, ASFV G ACD 00270, MGF 360-4L, MGF 360-6L, MGF 300-1L, MGF 300-2R, MGF 300-4L, MGF 360-8L, MGF 360-9L, MGF 360-10L, MGF 360-11L, MGF 505-1R, ASF G ACD 00120, MGF 110-8L, ASF G ACD 00210, ASF G ACD 00300, ASF G ACD 00320, ASF G ACD 00330, ASF G ACD 00350, ASF G ACD 00360, X69RDeletion site 2L7L, L8L, L9R, L10L, L11L, ASF G ACD 01870, MGF 100-3L, MGF 360-18RBold: Genes affecting attenuation

[0062]

[0063] Example 5. Confirmation of attenuation (safety) of ASF virus antigen (ASFV-CAP-YC) grown from CA-CAS-01-A cell line

[0064] The present inventors have confirmed the attenuation (safety) of the 14th passage ASF antigen (ASFV) propagated and attenuated from the CA-CAS-01-A cell line. 2 or 10 6 TCID 50 / ㎖ of ASFV was inoculated into 3-week-old pigs (Landrace or Danish Landrace, male). As a result, as shown in Fig. 6, it was confirmed that there was no effect on body temperature and survival rate for up to 24 days after inoculation in pigs vaccinated with ASF antigen. In addition, as shown in Fig. 7, no virus was detected in oral swabs, rectal swabs, or nasal swabs, and 10 sera were detected from 3 days after antigen inoculation. 2 ~10 3 TCID 50 It was detected as / ㎖ and completely disappeared on the 19th day, and in whole blood it was 10 3 ~10 5 TCID 50 The virus was detected at 100 ml / mL and then gradually decreased in quantity. In addition, the body temperature, survival rate, and clinical symptoms of all vaccinated individuals were observed for 3 weeks, and all groups showed a 100% survival rate, and no specific clinical symptoms due to ASFV infection were observed.

[0065] [Accession number]

[0066] Name of depositor: Korea Research Institute of Bioscience and Biotechnology

[0067] Accession number: KCTC14568BP

[0068] Date of acceptance: 20210512

[0069]

Claims

1. CA-CAS-01-A cell line deposited under accession number KCTC14568BP, capable of proliferating African swine fever virus.

2. A cell line according to claim 1, characterized in that the CA-CAS-01-A cell line is derived from the MA104 cell line (African green monkey kidney cell line).

3. In the first paragraph, the CA-CAS-01-A cell line is a cell line characterized in that it produces an attenuated African swine fever virus during a subculture process after infection with an African swine fever virus isolate. 4.(a) A step of infecting the CA-CAS-01-A cell line of paragraph 1 with an African swine fever virus isolate and then culturing the cell line; and (b) A method for mass production of African swine fever virus, comprising a step of purifying African swine fever virus from the culture solution of step (a).

5. A mass production method according to claim 4, characterized in that the African swine fever virus of step (b) is attenuated.

6. A vaccine composition for preventing African swine fever, comprising an African swine fever virus produced by the method of Article 4.

7. A vaccine composition according to claim 6, characterized in that the African swine fever virus is naturally attenuated.

8. In the 7th paragraph, the attenuation is MGF110-3L partial, MGF 110-4L, MGF 1105L6L, MGF 110-7L, 285L, ASFV G ACD 00160, MGF 100-1R, ASFV G ACD 00190, MGF 110-9L, MGF 110-11L_14L, ASFV G ACD 00240 MGF 110-12L, MGF 110-13La_b, ASFV G ACD 00270, MGF 360-4L, MGF 360-6L, MGF 300-1L, MGF 300-2R, MGF 300-4L, MGF 360-8L, MGF 360-9L, MGF A vaccine composition characterized in that one or more genes selected from the group consisting of 360-10L, MGF 360-11L, MGF 505-1R, L7L, L8L, L9R, L10L, and L11 are defective.

9. A vaccine composition according to claim 6, characterized in that the composition further comprises a pharmaceutically acceptable carrier or adjuvant.

Citation Information

Patent Citations

  • PAM-pcd163 cell line for isolating porcine reproductive and respiratory syndrome virus and vaccine using the same

    KR1020110123918A

  • Immortalized porcine renal cell line and the method for cultivating and proliferating porcine circovirus type 2 using the same

    KR1020150019910A

  • Heat Treatment Apparatus

    KR1020230174725A

  • Continuous stable cell line for identification of infectious african swine fever virus in clinical samples

    US20210333293A1